Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable

Claus Cursiefen, Joseph Colin, Reza Dana, Manuel Diaz-Llopis, Lana A Faraj, Salvador Garcia-Delpech, Gerd Geerling, Francis W Price, Lies Remeijer, Barry T Rouse, Berthold Seitz, Patricia Udaondo, Daniel Meller, Harminder Dua

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

The cornea is the clear window at the front of the eye and is the eye's main refractive medium. Its transparency is essential for vision. Corneal neovascularisation is a common clinical problem with serious consequences for vision; it can compromise corneal transparency and plays a major role in corneal graft rejection by breaching corneal immune privilege. In this review, we formulate a consensus on the unmet medical needs in the management of corneal neovascularisation and outline a framework for the clinical research that is needed to identify suitable agents to meet these needs.

Original languageEnglish
Pages (from-to)3-9
Number of pages7
JournalBritish Journal of Ophthalmology
Volume96
Issue number1
DOIs
Publication statusPublished - Jan 2012

Keywords

  • Angiogenesis Inhibitors/therapeutic use
  • Corneal Diseases/drug therapy
  • Corneal Neovascularization/drug therapy
  • Humans
  • Ophthalmology/standards
  • Practice Guidelines as Topic

Fingerprint

Dive into the research topics of 'Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable'. Together they form a unique fingerprint.

Cite this